A significant breakthrough lies in the identification of HER2-low breast cancer as a distinct, therapeutically targetable entity, defined by low-level HER2 expression and validated by trials of novel anti-HER2 antibody-drug conjugates. This evidence concerns the gene ERBB2 and breast carcinoma.